Get the Stockscreener App
2.98
5.99%
-0.19
After Hours:
2.85
-0.13
-4.36%
Neuraxis Inc stock is traded at $2.98, with a volume of 465.
It is down -5.99% in the last 24 hours and down -2.56% over the past month.
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
See More
Previous Close:
$3.17
Open:
$3.17
24h Volume:
465
Relative Volume:
0.08
Market Cap:
$21.69M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-3.6945
EPS:
-0.8066
Net Cash Flow:
-
1W Performance:
+2.76%
1M Performance:
-2.56%
6M Performance:
-4.49%
1Y Performance:
-21.58%
1-Day Range:
$2.98
$3.17
1-Week Range:
$2.76
$3.22
52-Week Range:
$1.80
$3.99
Neuraxis Inc Stock (NRXS) Company Profile
Name
Neuraxis Inc
Sector
Industry
Phone
(812) 689-0791
Address
11550 North Meridian Street, Suite 325, Carmel
Neuraxis Inc Stock (NRXS) Latest News
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation - Yahoo Finance
Zacks Initiates Coverage of NeurAxis With Neutral Recommendation - Zacks Investment Research
The Zacks Analyst Blog Highlights Costco Wholesale, Alibaba, GE Aerospace, Applied Energetics and NeurAxis - Yahoo Finance
NeurAxis (NASDAQ:NRXS) Trading Up 6% - Defense World
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - GlobeNewswire
NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - StockTitan
Neuraxis issues shares in equity financing By Investing.com - Investing.com Australia
Neuraxis issues shares in equity financing - Investing.com
Fishers startup prepares to go public - Greenfield Daily Reporter
NeurAxis (NASDAQ:NRXS) Stock Price Down 2.2% - Defense World
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024 - GlobeNewswire
NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024 - Yahoo Finance
Vagus Nerve Stimulators Market Projected to Witness Huge Growth - openPR
Neuraxis shareholders approve key proposals at annual meeting - Investing.com
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024 - GlobeNewswire
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024 - Marketscreener.com
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024 - StockTitan
NeurAxis revenue down 5.3% to USD 611.5K in Q2 2024 - Medical Buyer
NeurAxis, Inc. (NRXS) Q2 2024 Earnings Call Transcript - Seeking Alpha
Contrasting Sonova (OTCMKTS:SONVY) & NeurAxis (NASDAQ:NRXS) - Defense World
NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024 - MSN
NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024 - InvestorPlace
NeurAxis Reports Second Quarter 2024 Financial Results - GlobeNewswire
NeurAxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
NeurAxis Reports Second Quarter 2024 Financial Results - Yahoo Finance
Vagus Nerve Stimulators Market Is Booming Worldwide 2024-2031 | - openPR
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024 - GlobeNewswire
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024 - StockTitan
NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024 - Yahoo Finance
NeurAxis Gains $3 Million In Financing - MPO-mag
Head to Head Comparison: NeurAxis (NASDAQ:NRXS) vs. Positron (OTCMKTS:POSC) - Defense World
Vagus Nerve Stimulators Market Expected to Expand at a Steady - openPR
NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 - Marketscreener.com
ZUU Co. Ltd. executives purchase Pono Capital two shares worth $390 By Investing.com - Investing.com India
Neuraxis issues stock awards to non-employee directors - Investing.com
Blackstone director Baratta sells over $14 million in company stock By Investing.com - Investing.com UK
Head to Head Survey: NeurAxis (NASDAQ:NRXS) versus Electromed (NYSE:ELMD) - Defense World
NeurAxis (NASDAQ:NRXS) and Cutera (NASDAQ:CUTR) Head-To-Head Analysis - Defense World
NRXSNeurAxis, Inc. Latest Stock News & Market Updates - StockTitan
NeurAxis (NASDAQ:NRXS) Stock Price Down 3.3% - Defense World
Nexalin Technology (NASDAQ:NXL) & NeurAxis (NASDAQ:NRXS) Financial Review - Defense World
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with ... - GlobeNewswire
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with ... - Marketscreener.com
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure - GlobeNewswire Inc.
NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure - Yahoo Finance
Outset Medical (NASDAQ:OM) & NeurAxis (NASDAQ:NRXS) Head-To-Head Analysis - Defense World
Vagus Nerve Stimulators Market to Surpass US$ 1,158.7 Mn by 2031 with CAGR 9.7% - WhaTech
NeurAxis Reports First Quarter 2024 Financial Results - br.ADVFN.com
Viatris (VTRS) to Report Q1 Earnings: Is a Beat in Store? - MSN
Reviewing NeurAxis (NASDAQ:NRXS) and Outset Medical (NASDAQ:OM) - Defense World
NeurAxis, Inc. (NRXS) Q1 2024 Earnings Call Transcript - Seeking Alpha
Neuraxis Inc Stock (NRXS) Financials Data
There is no financial data for Neuraxis Inc (NRXS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Cap:
|
Volume (24h):